Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triptorelin - Debiopharm

Next Previous
Drug Profile

Triptorelin - Debiopharm

Alternative Names: ARVEKAP; AY 25650; BIM 21003; BN 52014; CL 118532; Debio 8200; Debio 8206; debio8200; Decapeptyl; Decapeptyl SR; Decapeptyl® LP; Diphereline; Gonapeptyl; Moapar; Pamorelin; Pamorelin LA; Salvacyl; Trelstar; Trelstar Depot; Triptodur; Triptorelin acetate; Triptorelin embonate; Triptorelin pamoate; Triptoreline; Tryptorelin; WY 42422

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tulane University
  • Developer AbbVie; Arbor Pharmaceuticals; Debiopharm; European Organisation for Research and Treatment of Cancer; Ipsen; Orient Europharma; United Laboratories
  • Class Antineoplastics; Antivirals; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precocious puberty
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Female infertility; Paraphilias; Precocious puberty; Prostate cancer; Uterine leiomyoma
  • Phase II Salivary gland cancer
  • No development reported Malignant melanoma

Most Recent Events

  • 13 Feb 2023 Ipsen completes a phase III trial in Precocious puberty (In children, In infants, In neonates) in China (IM) (NCT05029622)
  • 17 Nov 2022 Ipsen initiates enrolment in a phase-III trial for Prostate cancer (Late-stage disease, Metastatic disease) in China (NCT05590793)
  • 24 Oct 2022 Ipsen plans a phase III trial for Prostate cancer (Late-stage disease, Metastatic disease) (IM) in October 2022 (NCT05590793)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top